Drug Management of Prostate Cancer
(Sprache: Englisch)
Prostate cancer is the most common noncutaneous prostate cancer. Research has revealed several distinct malignancy and the second leading cause of cancer mechanisms of castration-resistant disease that may deaths among men in the United States. It is a...
Jetzt vorbestellen
versandkostenfrei
Buch (Gebunden)
Fr. 236.00
inkl. MwSt.
- Kreditkarte, Paypal, Rechnungskauf
- 30 Tage Widerrufsrecht
Produktdetails
Produktinformationen zu „Drug Management of Prostate Cancer “
Klappentext zu „Drug Management of Prostate Cancer “
Prostate cancer is the most common noncutaneous prostate cancer. Research has revealed several distinct malignancy and the second leading cause of cancer mechanisms of castration-resistant disease that may deaths among men in the United States. It is a critical converge in patients with disease progression on public health problem and remains incurable in the ADT. Many approaches are currently being evaluated metastatic setting with mortality that usually occurs as to improve the treatment of this condition and these a result of castration-resistant disease. fndings have identifed several potential targets for Since Huggins and Hodges' report of the dra- therapeutic intervention. These include drugs that are matic clinical effects of suppressing serum testos- more active or less toxic chemotherapy agents; drugs terone levels in men with advanced prostate cancer that induce androgen deprivation; drugs that target in 1941, hormone therapy (also called androgen the androgen receptor and/or androgen synthesis; deprivation therapy [ADT]) has become widely drugs that target specifc pathways, including ang- accepted as the mainstay of therapy for the treat- genesis and tyrosine kinase inhibitors, endothelin ment of advanced prostate cancer. ADT combined antagonists and matrix metalloproteinase inhibitors; with radiation therapy is a standard of care in the and immunologic approaches. Many of these agents treatment of men with locally advanced prostate seem promising and the rationale and effcacy of cancer on the basis of evidence that shows improved these emerging therapies remain to be validated in survival. The role of ADT in the management of future clinical trials.
Inhaltsverzeichnis zu „Drug Management of Prostate Cancer “
Section One Hormone TherapyChapter 1 Cell Biology of Prostate Cancer and Molecular Targets
Martin E. Gleave, Michael E. Cox, Yuzhuo Wang
Chapter 2 Luteinizing Hormone-Releasing Hormone (Lh-Rh) and its Agnostic, Antagonistic and Targeted Cytotoxic Analogs in Prostate Cancer
Andrew V. Schally and Norman L. Block
Chapter 3 Nuclear Receptor Coregulators: Promising Therapeutic Targets for the Treatment of Prostate Cancer
Hannelore V. Heemers and Donald J. Tindall
Chapter 4 Androgens and Prostate Cancer
Douglas K. Price and Ann W. Hsing
Chapter 5 Androgen Receptor Biology in Prostate Cancer
Edward P. Gelmann
Chapter 6 Androgen Receptor Antagonists
Howard C. Shen, Mary-Ellen Taplin, Steven P. Balk
Chapter 7 5 alpha Reductase Inhibitors in Prostate Cancer
Zoran Culig
Chapter 8 Adrenolytic Therapies in Castration Resistant Prostate Cancer
Terence W. Friedlander and Charles J. Ryan
Chapter 9 Androgen Deprivation Therapy
Nima Sharifi
Chapter 10 Pharmacogenetics of the Androgen Metabolic Pathway
Francine Zanchetta Coehlo Marques and Juergen Reichardt
Section Two Chemotherapy
Chapter 11 Mitoxantrone
Patricia Halterman, Nicholas J. Vogelzang, Alireza Farabishahadel, Oscar B. Goodman, Jr.
Chapter 12 Docetaxel
Courtney K. Phillips and Daniel P. Petrylak
Chapter 13 Beyond Docetaxel: Emerging Agents in the Treatment of Advanced Prostate Cancer
Jonathan Rosenberg
Chapter 14 Platinum Agents in Prostate Cancer
Ashley Brick, Junyang Niu, Jiaoti Huang, William K. Oh
Chapter 15 Clinical Pharmacology and Pharmacogenetics of Chemotherapy in Prostate Cancer
Tristan M. Sissung and William D. Figg
Chapter 16 Microtubule Targeting Agents
Antonio Tito Fojo and David E. Adelberg
Section Three Angiogenesis
Chapter 17 Principles of Antiangiogenic Therapy
Cindy H. Chau and William D. Figg
Chapter 18 Bevacizumab in Advanced Prostate Cancer
Aymen A. Elfiky and William Kevin Kelly
Chapter 19 Thalidomide and Analogs
Erin
... mehr
R. Gardner, Giuseppe Di Lorenzo, and William D. Figg
Chapter 20 Investigational Angiogenesis Inhibitors
Jeanny B. Aragon-Ching, William Dahut, MD
Chapter 21 Pharmacogenetics of Angiogenesis
Guido Bocci, Giuseppe Pasqualetti, Antonello Di Paolo, Francesco Crea, Mario Del Tacca, Romano Danesi
Section Four Bone Metastasis
Chapter 22 Pathophysiology of Prostate Cancer Bone Metastasis
Evan T. Keller and Christopher L. Hall
Chapter 23 Radiopharmaceuticals
Oliver Sartor and Damerla R. Venugopal
Chapter 24 Bisphosphonates for Prevention and Treatment of Bone Metastases
Philip J. Saylor and Matthew R. Smith
Chapter 25 Endothelin Receptors as Therapeutic Targets in Castrate Resistant Prostate Cancer
Joel B. Nelson
Chapter 26 Calcitriol and Vitamin D Analogs
Ana R. Jensen, Russell Z. Szmulewitz, Tomasz M. Beer, Edwin M. Posadas
Chapter 27 Cancer Immunology, Immunotherapeutics and Vaccine Approaches
Ravi A. Madan, James L. Gulley, Jackie Celestin, Philip M. Arlen, Jeffrey Schlom
Chapter 28 Sipuleucel-T (APC8015): Active Cellular Immunotherapy for Advanced Metastatic Castrate-Resistant Prostate Cancer
Celestia S. Higano and Mark W. Frohlich
Chapter 29 GM-CSF Genes Transduced Prostate Cancer Vaccines: GVAX
Lalit R. Patel and Jonathan W. Simons
Chapter 30 CTLA-4 Blockade for Prostate Cancer Treatment
Andrea L. Harzstark and Lawrence Fong
Section Five - Prevention
Chapter 31 Prostate Cancer Chemoprevention Strategies
Howard L. Parnes, Margaret G. House, Joseph A. Tangrea
Chapter 32 Diet and Prostate Cancer Incidence, Recurrence, and Progression Risk
June M. Chan and Erin L. Richman
Chapter 33 Inflammation as a Target in Prostate Cancer
Marshall Scott Lucia, James R. Lambert, Elizabeth A. Platz, Angelo M. De Marzo
Section Six Drug Development
Chapter 34 Challenges for the Development of New Agents in Prostate Cancer
Ajjai S. Alva, Deborah A. Bradley, Maha Hussain
Chapter 35 FDA Approval of Prostate Cancer
Chapter 20 Investigational Angiogenesis Inhibitors
Jeanny B. Aragon-Ching, William Dahut, MD
Chapter 21 Pharmacogenetics of Angiogenesis
Guido Bocci, Giuseppe Pasqualetti, Antonello Di Paolo, Francesco Crea, Mario Del Tacca, Romano Danesi
Section Four Bone Metastasis
Chapter 22 Pathophysiology of Prostate Cancer Bone Metastasis
Evan T. Keller and Christopher L. Hall
Chapter 23 Radiopharmaceuticals
Oliver Sartor and Damerla R. Venugopal
Chapter 24 Bisphosphonates for Prevention and Treatment of Bone Metastases
Philip J. Saylor and Matthew R. Smith
Chapter 25 Endothelin Receptors as Therapeutic Targets in Castrate Resistant Prostate Cancer
Joel B. Nelson
Chapter 26 Calcitriol and Vitamin D Analogs
Ana R. Jensen, Russell Z. Szmulewitz, Tomasz M. Beer, Edwin M. Posadas
Chapter 27 Cancer Immunology, Immunotherapeutics and Vaccine Approaches
Ravi A. Madan, James L. Gulley, Jackie Celestin, Philip M. Arlen, Jeffrey Schlom
Chapter 28 Sipuleucel-T (APC8015): Active Cellular Immunotherapy for Advanced Metastatic Castrate-Resistant Prostate Cancer
Celestia S. Higano and Mark W. Frohlich
Chapter 29 GM-CSF Genes Transduced Prostate Cancer Vaccines: GVAX
Lalit R. Patel and Jonathan W. Simons
Chapter 30 CTLA-4 Blockade for Prostate Cancer Treatment
Andrea L. Harzstark and Lawrence Fong
Section Five - Prevention
Chapter 31 Prostate Cancer Chemoprevention Strategies
Howard L. Parnes, Margaret G. House, Joseph A. Tangrea
Chapter 32 Diet and Prostate Cancer Incidence, Recurrence, and Progression Risk
June M. Chan and Erin L. Richman
Chapter 33 Inflammation as a Target in Prostate Cancer
Marshall Scott Lucia, James R. Lambert, Elizabeth A. Platz, Angelo M. De Marzo
Section Six Drug Development
Chapter 34 Challenges for the Development of New Agents in Prostate Cancer
Ajjai S. Alva, Deborah A. Bradley, Maha Hussain
Chapter 35 FDA Approval of Prostate Cancer
... weniger
Bibliographische Angaben
- 2010, XVIII, 430 Seiten, 22 farbige Abbildungen, Masse: 19,8 x 26,6 cm, Gebunden, Englisch
- Herausgegeben: William D. Figg, Cindy H. Chau, Eric J. Small
- Verlag: Springer, Berlin
- ISBN-10: 1603278311
- ISBN-13: 9781603278317
- Erscheinungsdatum: 17.09.2010
Sprache:
Englisch
Rezension zu „Drug Management of Prostate Cancer “
From the reviews: "For medical oncologists, trainees, researchers, and those in the pharmaceutical industry, Figg ... offer a comprehensive and concise summary of the pharmacological treatments for prostate cancer, both current standard and investigative options. The 36 chapters ... focus on a multidisciplinary care approach and cover hormone therapy, chemotherapy, angiogenesis, therapy for bones metastases, immunotherapy, chemoprevention, and drug development. Cell biology and molecular targets are also discussed." (SciTech Book News, December, 2010) "The 36 chapters in this book ... read as independent discussions of many of the most recent discoveries in the area of drug management of prostate cancer. ... suitable for medical students, physicians in training, physicians (especially medical oncologists), scientists, translational researchers, and members of the pharmaceutical industry. ... An important aspect of this book is that the data represents updated, state-of-the-art information, making it valuable for daily reference. ... an excellent resource for readers interested in the management of advanced prostate cancer ... ." (Jianqing Lin, Doody's Review Service, December, 2010) "This treatise is an exhaustive description of the application of drug management of prostate cancer involving both standard care and investigational agents. ... this book will give the reader a detailed insight about the current knowledge from clinical trials into the drug treatment of prostate tumours. The urologists, medical oncologist and others involved in the treatment of the prostate cancer will find in this work a complete review of where we are now." (M. Hornak, Neoplasma, March, 2011) "This textbook by W.D. Figg and co-authors ... makes an exhaustive overview of present and future medical therapies of prostate cancer. ... This book provides the reader with comprehensive information about pharmacological treatments of prostate cancer. All chapters are concise and most of them
... mehr
are well-illustrated. We recommend this textbook to urologists, oncologists who are involved in prostate cancer management, and to all physicians and students who want to update their knowledge in prostate cancer management." (European Urology Today, April/May, 2011)
... weniger
Pressezitat
From the reviews:"For medical oncologists, trainees, researchers, and those in the pharmaceutical industry, Figg ... offer a comprehensive and concise summary of the pharmacological treatments for prostate cancer, both current standard and investigative options. The 36 chapters ... focus on a multidisciplinary care approach and cover hormone therapy, chemotherapy, angiogenesis, therapy for bones metastases, immunotherapy, chemoprevention, and drug development. Cell biology and molecular targets are also discussed." (SciTech Book News, December, 2010)
"The 36 chapters in this book ... read as independent discussions of many of the most recent discoveries in the area of drug management of prostate cancer. ... suitable for medical students, physicians in training, physicians (especially medical oncologists), scientists, translational researchers, and members of the pharmaceutical industry. ... An important aspect of this book is that the data represents updated, state-of-the-art information, making it valuable for daily reference. ... an excellent resource for readers interested in the management of advanced prostate cancer ... ." (Jianqing Lin, Doody's Review Service, December, 2010)
"This treatise is an exhaustive description of the application of drug management of prostate cancer involving both standard care and investigational agents. ... this book will give the reader a detailed insight about the current knowledge from clinical trials into the drug treatment of prostate tumours. The urologists, medical oncologist and others involved in the treatment of the prostate cancer will find in this work a complete review of where we are now." (M. Hornák, Neoplasma, March, 2011)
"This textbook by W.D. Figg and co-authors ... makes an exhaustive overview of present and future medical therapies of prostate cancer. ... This book provides the reader with comprehensive information about pharmacological treatments of prostate cancer. All
... mehr
chapters are concise and most of them are well-illustrated. We recommend this textbook to urologists, oncologists who are involved in prostate cancer management, and to all physicians and students who want to update their knowledge in prostate cancer management." (European Urology Today, April/May, 2011)
... weniger
Kommentar zu "Drug Management of Prostate Cancer"
0 Gebrauchte Artikel zu „Drug Management of Prostate Cancer“
| Zustand | Preis | Porto | Zahlung | Verkäufer | Rating |
|---|
Schreiben Sie einen Kommentar zu "Drug Management of Prostate Cancer".
Kommentar verfassen